[{"indications": "Indications\u00a0Parkinson\u2019s disease, used alone or\r\nas an adjunct to co-beneldopa\r\nor co-careldopa; moderate to severe restless legs syndrome", "name": "PRAMIPEXOLE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Dopamine-receptor agonists", "PRAMIPEXOLE", "Modified release"], "cautions": "Cautions\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists; psychotic disorders; ophthalmological\r\ntesting recommended (risk of visual disorders); severe cardiovascular disease; risk of\r\npostural hypotension (especially on initiation)\u2014monitor blood pressure; interactions: Appendix 1 (pramipexole)", "side-effects": "Side-effects\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists; also\r\nnausea, constipation, vomiting, weight changes, decreased appetite,\r\nhypotension (including postural hypotension), peripheral oedema, dizziness,\r\ndyskinesia, hyperkinesia, drowsiness (including %s\n(From Dopamine-receptor agonists: British National Formulary)\nDrivingSudden onset of sleep\u00a0Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and dopamine-receptor agonists.Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.Hypotensive reactions\u00a0Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.),\r\nheadache, sleep disturbances, confusion, hallucinations, restlessness,\r\nvisual disturbances; less commonly hiccups, cardiac\r\nfailure, syncope, pneumonia, dyspnoea, binge eating, compulsive behaviour\r\n(\n(From Dopamine-receptor agonists: British National Formulary)\nPatients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.), amnesia,\r\ndelusion, paranoia, pruritus, rash; also reported paradoxical worsening of restless legs syndrome", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204132.htm", "doses": ["Doses and strengths are stated in terms\r\nof pramipexole (base); equivalent strengths in\r\nterms of pramipexole dihydrochloride monohydrate\r\n(salt) are as follows: 88\u00a0micrograms base \u2261 125\u00a0micrograms\r\nsalt; 180\u00a0micrograms base \u2261 250\u00a0micrograms salt; 350\u00a0micrograms base \u2261 500\u00a0micrograms salt;700\u00a0micrograms\r\nbase \u2261 1\u00a0mg salt", "Parkinson\u2019s disease, adult over\r\n18 years, initially 88\u00a0micrograms 3 times daily, dose doubled every\r\n5\u20137 days if tolerated to 350\u00a0micrograms 3 times daily; further increased\r\nif necessary by 180\u00a0micrograms 3 times daily at weekly intervals;\r\nmax. 3.3\u00a0mg daily in 3 divided doses", "During dose titration and maintenance, levodopa dose may be reduced", "Restless legs syndrome, adult over 18 years, initially 88\u00a0micrograms once daily 2\u20133 hours before\r\nbedtime, dose doubled every 4\u20137 days if necessary; max. 540\u00a0micrograms\r\ndaily", "During dose titration and maintenance, levodopa\r\ndose may be reduced according to response", "Name[Mirapexin\u00ae Prolonged Release (Boehringer Ingelheim) ] Tablets, m/r, pramipexole 260\u00a0micrograms,\r\nnet price 30-tab pack = \u00a328.65; 520\u00a0micrograms, 30-tab pack = \u00a357.30;\r\n1.05\u00a0mg, 30-tab pack = \u00a3114.60; 1.57\u00a0mg, 30-tab pack = \u00a3171.90; 2.1\u00a0mg,\r\n30-tab pack = \u00a3229.20; 2.62\u00a0mg, 30-tab pack = \u00a3286.50; 3.15\u00a0mg, 30-tab\r\npack = \u00a3343.80. \r\n    Label:\r\n    10, 25, counselling, driving, see notes aboveImportant\u00a0Doses and strengths are stated in terms\r\nof pramipexole (base); equivalent strengths in terms of pramipexole\r\ndihydrochloride monohydrate (salt) are as follows: 260\u00a0micrograms\r\nbase \u2261 375\u00a0micrograms salt;520\u00a0micrograms base \u2261 750\u00a0micrograms\r\nsalt;1.05\u00a0mg base \u2261 1.5\u00a0mg salt;1.57\u00a0mg base \u2261\r\n2.25\u00a0mg salt;2.1\u00a0mg base \u2261 3\u00a0mg salt;2.62\u00a0mg base\r\n\u2261 3.75\u00a0mg salt;3.15\u00a0mg base \u2261 4.5\u00a0mg saltDose\u00a0Parkinson\u2019s disease (with or without co-beneldopa or co-careldopa), adult over 18 years, initially 260\u00a0micrograms once\r\ndaily, dose doubled every 5\u20137 days to 1.05\u00a0mg once daily; further\r\nincreased if necessary by 520\u00a0micrograms daily at weekly intervals;\r\nmax. 3.15\u00a0mg once dailyNote\u00a0During dose titration and maintenance, levodopa\r\ndose may be reduced according to response"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk\u2014no information\r\navailable"}, {"indications": "Indications\u00a0Parkinson\u2019s disease, used alone or\r\nas an adjunct to co-beneldopa\r\nor co-careldopa; moderate to severe restless legs syndrome", "name": "PRAMIPEXOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Dopamine-receptor agonists", "PRAMIPEXOLE"], "cautions": "Cautions\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists; psychotic disorders; ophthalmological\r\ntesting recommended (risk of visual disorders); severe cardiovascular disease; risk of\r\npostural hypotension (especially on initiation)\u2014monitor blood pressure; interactions: Appendix 1 (pramipexole)", "side-effects": "Side-effects\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists; also\r\nnausea, constipation, vomiting, weight changes, decreased appetite,\r\nhypotension (including postural hypotension), peripheral oedema, dizziness,\r\ndyskinesia, hyperkinesia, drowsiness (including %s\n(From Dopamine-receptor agonists: British National Formulary)\nDrivingSudden onset of sleep\u00a0Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and dopamine-receptor agonists.Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.Hypotensive reactions\u00a0Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.),\r\nheadache, sleep disturbances, confusion, hallucinations, restlessness,\r\nvisual disturbances; less commonly hiccups, cardiac\r\nfailure, syncope, pneumonia, dyspnoea, binge eating, compulsive behaviour\r\n(\n(From Dopamine-receptor agonists: British National Formulary)\nPatients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.), amnesia,\r\ndelusion, paranoia, pruritus, rash; also reported paradoxical worsening of restless legs syndrome", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204131.htm", "doses": ["Doses and strengths are stated in terms\r\nof pramipexole (base); equivalent strengths in\r\nterms of pramipexole dihydrochloride monohydrate\r\n(salt) are as follows: 88\u00a0micrograms base \u2261 125\u00a0micrograms\r\nsalt; 180\u00a0micrograms base \u2261 250\u00a0micrograms salt; 350\u00a0micrograms base \u2261 500\u00a0micrograms salt;700\u00a0micrograms\r\nbase \u2261 1\u00a0mg salt", "Parkinson\u2019s disease, adult over\r\n18 years, initially 88\u00a0micrograms 3 times daily, dose doubled every\r\n5\u20137 days if tolerated to 350\u00a0micrograms 3 times daily; further increased\r\nif necessary by 180\u00a0micrograms 3 times daily at weekly intervals;\r\nmax. 3.3\u00a0mg daily in 3 divided doses", "During dose titration and maintenance, levodopa dose may be reduced", "Restless legs syndrome, adult over 18 years, initially 88\u00a0micrograms once daily 2\u20133 hours before\r\nbedtime, dose doubled every 4\u20137 days if necessary; max. 540\u00a0micrograms\r\ndaily"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk\u2014no information\r\navailable"}]